Literature DB >> 1371516

Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus.

L D Papsidero1, R P Dittmer, L Vaickus, B J Poiesz.   

Abstract

Monoclonal antibodies (MAbs) raised against human T-cell lymphotropic virus type I (HTLV-I) recognized five distinct antigenic domains of viral env gene-encoded proteins. By using recombinant env proteins and synthetic peptides as mapping antigens, it was determined that the most immunogenic region represented a central portion of the retroviral surface protein (domain 2; amino acids 165 to 191). However, only a single MAb was able to react strongly with native viral proteins. This antibody (clone 6C2) was directed to an epitope within domain 4 (amino acids 210 to 306) of the retroviral env gene and reacted with envelope proteins in both HTLV-I and HTLV-II, as determined by immunoprecipitation, solid-phase binding, and immunoblotting. No reactivity against envelope components of other human retroviruses, including human immunodeficiency virus types 1 and 2, was present. Flow cytometry data demonstrated that MAb 6C2 reacted with cell lines chronically infected with HTLV-I or HTLV-II and also with surface antigens expressed on fresh adult T-cell leukemia cells, following up-regulation with interleukin-2. By a chemiluminescence immunoassay procedure, picogram amounts of viral surface protein could be detected in the unconcentrated supernatants of HTLV-infected cell lines and in diagnostic cultures. Levels of env and gag proteins released by cells into culture supernatants were not directly related to percent expression of cell surface viral-coat proteins. Further, the molar ratio of p19 to gp46 in conditioned media varied from strain to strain, possibly reflecting differences in viral assembly or packaging mechanisms. MAb 6C2 will be of value in characterizing the biochemical and immunological behavior of retroviral env gene proteins and in studying the interaction of HTLV-I and HTLV-II with their receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371516      PMCID: PMC265059          DOI: 10.1128/jcm.30.2.351-358.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  49 in total

1.  A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE.

Authors:  J V PULVERTAFT
Journal:  J Clin Pathol       Date:  1965-05       Impact factor: 3.411

2.  HTLV-I polymyositis in a patient also infected with the human immunodeficiency virus.

Authors:  C A Wiley; M Nerenberg; D Cros; M C Soto-Aguilar
Journal:  N Engl J Med       Date:  1989-04-13       Impact factor: 91.245

3.  Immunodetection of human T-cell lymphotropic virus type I core protein in biological samples by using a monoclonal antibody immunoassay.

Authors:  L Papsidero; F Swartzwelder; M Sheu; R Montagna; G Ehrlich; S Bhagavati; H Dosik; J Sninsky; B Poiesz
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

4.  Envelope proteins of human T cell leukemia virus type I: characterization by antisera to synthetic peptides and identification of a natural epitope.

Authors:  T D Copeland; W P Tsai; Y D Kim; S Oroszlan
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

5.  Isolation of a new human retrovirus from West African patients with AIDS.

Authors:  F Clavel; D Guétard; F Brun-Vézinet; S Chamaret; M A Rey; M O Santos-Ferreira; A G Laurent; C Dauguet; C Katlama; C Rouzioux
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

6.  Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping.

Authors:  L D Papsidero; M Sheu; F W Ruscetti
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

7.  Detection of sequences homologous to human retroviral DNA in multiple sclerosis by gene amplification.

Authors:  S J Greenberg; G D Ehrlich; M A Abbott; B J Hurwitz; T A Waldmann; B J Poiesz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

8.  Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens.

Authors:  P Parham; C J Barnstable; W F Bodmer
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

9.  High prevalence of HTLV-II among intravenous drug abusers: PCR confirmation and typing.

Authors:  S Kwok; D Gallo; C Hanson; N McKinney; B Poiesz; J J Sninsky
Journal:  AIDS Res Hum Retroviruses       Date:  1990-04       Impact factor: 2.205

10.  High frequency of human T-cell leukemia-lymphoma virus type II infection in New Mexico blood donors: determination by sequence-specific oligonucleotide hybridization.

Authors:  B Hjelle; R Scalf; S Swenson
Journal:  Blood       Date:  1990-08-01       Impact factor: 22.113

View more
  4 in total

1.  Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.

Authors:  K G Hadlock; J Rowe; S Perkins; P Bradshaw; G Y Song; C Cheng; J Yang; R Gascon; J Halmos; S M Rehman; M S McGrath; S K Foung
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Infection of peripheral blood mononuclear cells and cell lines by cell-free human T-cell lymphoma/leukemia virus type I.

Authors:  N Fan; J Gavalchin; B Paul; K H Wells; M J Lane; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

3.  Immunoelectron microscopic study of HTLV-II-producing cells with an anti-envelope gp46 monoclonal antibody.

Authors:  N Ohara; K Hayashi; K Miyamoto; K Takahashi; Y Ohtsuki; T Akagi
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.

Authors:  K G Hadlock; J Rowe; S K Foung
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.